期刊文献+

洛沙坦对肥胖Zucker大鼠肾组织环氧化酶2表达的影响 被引量:2

Effect of losartan on the cyclooxygenase 2 expression in the obese Zucker rat kidney
原文传递
导出
摘要 目的探讨血管紧张素Ⅱ(AngⅡ)1型受体拮抗剂(ARB)洛沙坦对代谢综合征(MS)肾组织环氧化酶2(COX-2)表达的影响及其机制。方法把7周大的MS模型肥胖Zucker大鼠随机分成洛沙坦处理组和未处理组,以瘦Zucker大鼠为对照组,连续给药4个月后观察肾组织内COX-2的表达。另外,用AngⅡ刺激6 h的系膜细胞和用从微型渗透泵灌注AngⅡ5 d的C57BL/6小鼠肾脏提取的肾皮质,观察COX-2的表达。采用RT-PCR和Western印迹法分别检测COX-2 mRNA和蛋白的表达。结果洛沙坦可阻止肥胖Zucker大鼠肾组织内COX-2表达增加。AngⅡ直接刺激可以诱导系膜细胞和肾组织内COX-2表达增加。结论AngⅡ可以调控MS肾组织内COX-2表达增加。ARB可以通过抑制COX-2的表达保护MS肾脏,这对应用非COX-2抑制剂来保护MS肾脏具有重要的意义。 Objective To investigate the effect of angiotensin Ⅱ (AngⅡ) type 1 receptor blocker losartan on the cyclooxygenase 2 (COX-2) expression in metabolic syndrome (MS)kidney. Methods Seven-week-old male obese Zucker rats, a model of MS, were randomly divided into losartan treated and untreated group, and lean Zucker rats were used as controls. The obese Zucker rats of treated group received losartan for 4 months continuously. COX-2 expression was examined for all rats after 4 months. Ang Ⅱ-stimulated mesangial ceils and cortical tissue from AngⅡ-infused C57BL/6 mouse kidney by osmotic minipumps were used in this study. RNA and protein were obtained from renal cortical tissue or mesangial ceils for RT-PCR and Western blot. Results Compared to the lean controls, obese Zucker rats showed a significant increase of COX-2 expression in the renal cortical tissue and these abnormalities were prevented by administration of losartan. Furthermore, the direct stimulation of Ang Ⅱ increased COX-2 expression in mesangial ceils in vitro and renal cortical tissue in vivo. Conclusions MS-induced COX-2 expression in the kidney is regulated by Ang Ⅱ. Losartan as a non COX-2 inhibitor can protect MS kidney, at least in part, by inhibition of COX-2 activation.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2006年第12期749-752,共4页 Chinese Journal of Nephrology
关键词 洛沙坦 血管紧张素Ⅱ 环氧化酶2 代谢综合征 Losartan Angiotensin Ⅱ Cyclooxygenase 2 Metabolic syndrome
  • 相关文献

参考文献8

  • 1边琪,袁伟杰,鲁维维,叶菡洋,崔若兰.代谢综合征及其代谢因子与慢性肾损害相关性的临床研究[J].中华肾脏病杂志,2005,21(7):389-393. 被引量:26
  • 2Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension,1992,19:110-115.
  • 3Gassler N, Elger M, Kranzlin B,et al. Podocyte injury underlies the progressiion of focal segmented glomerulosclerosis in fa/fa zucker rats. Kidney Int,2001,60:106-116.
  • 4Goncalves AR, Fujihara CK, Mattar AL, et al. Renal expression of COX-2, ANG Ⅱ, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol,2004, 286: F945-F954.
  • 5Cheng HF, Wang C J, Moeckel GW, et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int, 2002, 62:929-939.
  • 6Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults :finding from the Third National Health and Nutrition Examination Survey. JAMA, 2002,287 :356-359.
  • 7Wong D, Wang M, Cheng Y, et al. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curt Opin Pharmacol, 2005, 5 : 204-210.
  • 8Vazifi ND, Xu ZG, Shahkarami A, et al. AT-1 receptor,inflammatory mediators, MAP kinase activities and matrix proteins in the obese Zueker rat aorta: effect of AT-1 blockade. Kidney Int, 2005, 68 : 2787-2793.

二级参考文献13

  • 1Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X).Diabetes, 1992, 41:715-722.
  • 2Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA, 2002, 287:356-359.
  • 3Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetes Care, 2001, 24:683-689.
  • 4Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total cardiovascular disease mortality in middleaged men. JAMA, 2002, 288:2709-2716.
  • 5Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol, 2002, 13:1626-1634.
  • 6Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat1, 1994.1-407.
  • 7Chen J, Muntner P, Hamm LL, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults.J Am Soc Nephrol, 2003,14:469-477.
  • 8Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther,2004,11:41-54.
  • 9Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int, 1997,51:1908-1919.
  • 10Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int, 2000,58:293-301.

共引文献25

同被引文献50

  • 1余臣祖,张朝宁,刘国安.实验性2型糖尿病动物模型研究进展[J].医学综述,2006,12(1):41-42. 被引量:33
  • 2张松筠,张庆九,苏胜偶,张力辉.2型糖尿病模型db/db小鼠肾上腺超微结构观察[J].河北医科大学学报,2006,27(5):342-343. 被引量:3
  • 3刘冬妍,李学旺,李航,文煜冰,段琳,李艳.低盐诱导的致密斑细胞环氧化酶2表达与p38丝裂素激活蛋白激酶信号通路[J].中华肾脏病杂志,2006,22(11):697-701. 被引量:6
  • 4Shirwaikar A, Rajendran K, Barik R. Effect of aqueous bark extract of a Garuga pinnata Roxb. In streptozotocin-nicotinamide induced type- Ⅱ diabetes mellitus[J]. J Ethnopharmacol, 2006, 107(2): 285-290.
  • 5Chang KC, Tsenq CD, Chou TF, et al. Arterial stiffening and cardiac hypertrophy in a new rat model of type 2 diabetes[J]. Eur J Clin Invest, 2006, 36(1): 1-7.
  • 6Asqhar Z, Yan D, Chan F, et al. Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes [J]. Diabetoloqia, 2006, 49(1): 90-99.
  • 7Liu Y, Wang Z, Yin W, et al. Severe insulin resistance and moderate glomerulosclerosis in a minipig model induced by high-fat/high-sucrose/high-cholesterol diet[J]. Exp Anim, 2007, 56(1): 11-20.
  • 8Sahin K, Onderci M, Tuzcu M, et al. Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat [J]. Metabolim, 2007, 56(9): 1233-1240.
  • 9Wang HJ, Jin YX, Shen W, et al. Low dose streptozotocin (STZ) combined with high energy intake can effectively induce type 2 diabetes through altering the related gene expression[J]. Asia Pac J Clin Nutr, 2007, 16(1): 412-417.
  • 10Ninichuk V, Kulkarni O, Clauss S, et al. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/ db mice. An accelerated model of advanced diabetic nephropathy[J]. Eur J Med Res, 2007, 12(8): 351-355.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部